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Abstract Transcriptional regulation of insulin gene expression 
is achieved by an interplay of tissue-specific and ubiquitous cis- 
and trans-acting elements. E-box like motifs and TAAT-motifs 
were shown to play a crucial role in initiating insulin gene tran- 
scription. Studying the AT-rich region of the rat insulin-II pro- 
moter between nucleotides -212 and -196, we observed a base 
difference at -211,  an adenosine instead of a cytidine, compared 
to the previously reported sequence (EMBL Accession No. 
J00748). Sequence analysis of promoter fragments from different 
rat strains showed that adenosine at position -211 represents the 
wild type (EMBL Accession No. X82162). This base exchange 
leads to the formation of an additional TAAT-motif, i.e. TAAT3, 
at the complementary DNA strand directly upstream of the pre- 
viously studied TAAT2 motif, formerly named CT-2. Here we 
show that the newly identified motif TAAT3 is involved in 
(i) transcriptional control in vivo, (ii) in vitro DNA/protein inter- 
actions, and that (iii) TAAT1, TAAT2 and TAAT3 are binding 
sites for the homeodomain-containing factor IPF-1. 
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were mutationally sensitive in transient expression studies and 
showed asimilar etardation pattern in electrophoretic mobility 
shift assays. In a very recent study Peshavaria et al. [17] con- 
firmed the data for the distal region between -201 and -196 
bp and showed that it represents a binding site for the homeo- 
domain containing factor STF-1/IPF-1/1DX-1. Furthermore, 
studying the region containing the CT-2 element we observed 
a difference in the nucleotide sequence at promoter position 
-211: an adenosine instead of the so far described cytid- 
ine. This base exchange would lead to the formation of an 
additional TAAT-motif at the lower DNA-strand irectly up- 
stream of the upper-strand distal TAAT-motif (CT-2). In this 
study we demonstrate hat the newly identified TAAT-motif, 
called here TAAT3, represents he 'wild type' situation of this 
promoter egion and, further, that TAAT3 is involved in 
(i) transcriptional control in vivo, (ii) in vitro DNA-protein 
interactions, asdemonstrated byDNase I footprinting analysis 
and methylation i terference assays, and (iii) represents a bind- 
ing site for the homeodomain-containing factor IPF-1. 
2. Material and methods 
I. Introduction 
The expression of the insulin gene in adult organisms is 
restricted to pancreatic t-cells. Multiple elements exhibiting 
both positive and negative ffects contribute to its transcrip- 
tional control (for review see [1 3]). At least two known cis- 
elements seem to play a crucial role in both the tissue-specific 
and the glucose-responsive regulation of insulin gene transcrip- 
tion: E-box like sequences with a consensus sequence 
GCCANNTG, and TAAT-boxes. The E-box like motifs such 
as IEB2/Far- and IEBl/Nir-boxes [4,5] in the rat insulin-I pro- 
moter, ICE [6] and part of RIPE3 [7] in the rat insulin-II 
promoter, and the GC-I motif in the human insulin promoter 
[8] are binding sites for factors of the basic helix-loop-helix 
family. Whereas this class of transcriptional control elements 
is relatively well studied in insulin gene regulation, the investi- 
gation of the TAAT-motifs, representing binding sites for 
homeodomain-containing factors, was so far mainly restricted 
to the rat insulin-I gene [9,10] and the human insulin gene 
[8,11-15]. 
In a previous report we showed the impact of two TAAT- 
motifs between ucleotides -82/ -76 and -202/-196 (CT-1 
and CT-2, respectively) of the rat insulin II promoter in tran- 
scription initiation in insulin producing cells [16]. Both elements 
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2.1. DNA-preparation and sequencing 
Genomic DNA from Wistar and Sprague-Dawley rats was prepared 
as described in [18]. DNA from BB- and DA-rats were gifts from Dr. 
I. Kl6ting (Institut for Diabetes, EMAU Greifswald, Karlsburg). To 
amplify DNA-fragments of the rat insulin-II promoter using PCR we 
used as the upstream primer 5'-CTCTCTGAGACAATGTC-Y and as 
the downstream primer 5'-GTTACTGAACCCCACT-3', and Ultma- 
polymerase (Perkin Elmer) or Taq-Polymerase (Amersham) as ther- 
mostable DNA-polymerases. Generated PCR products were subcloned 
directly into the T-tailed vector pT7Blue (Novagen) and were verified 
by either cycle sequencing using the Dye Termination Technique and the 
373A-sequencer (Applied Biosystems) orthe T7-DNA-polymerase se-
quencing kit (Pharmacia). The nucleotide s quence data reported in this 
paper was deposited under accession number X82162 in EMBL/Gen- 
Bank/DDJB. 
2.2. Plasmid construction 
Both plasmids p211A and p211C contain the rat insulin-II gene 
promoter (-218bp/+ 129bp) fused to the reporter gene CAT, but differ 
in the promoter sequence atposition -211 in containing an adenosine 
(p211A) or a cytidine (p211C). p211A is identical with pBRINSII- 
218CAT [16]. p211C was generated on the basis of pBRINSII-218CAT 
by site-directed mutagenesis using the MutaGene In Vitro Mutagenesis 
Kit (Bio-Rad) and with the mutagenic primer 5"-CTTAGGGTAAT- 
TAGAGTCTTAAGAGGGGCT-3'. After performing mutagenesis 
the promoter fragment was subcloned into the promoterless vector 
pBSVOCAT [19] and the sequence was verified. 
2.3. Cell culture and transfection 
Insulin-producing cells, HIT M2.2.2, were grown in RPMI 1640 
supplemented with 40 units/ml penicillin, 40 pg/ml streptomycin, 2 mM 
glutamine, and 10% fetal calf serum. Cells were transfected using the 
calcium phosphate coprecipitation technique as described in[20] using 
20 pg CsCl-purified CAT expression vector and 5/~g pRSVflgal [21] per 
100 mm dish. Cells were harvested 48 h after transfection, and cell 
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lysates analyzed for CAT- and fl-gal activities [22,23]. The fl-galactosi- 
dase values were used to normalize the individual test CAT levels. 
2.4. In vitro DNA-protein interaction 
Crude nuclear extracts were prepared from HIT M2.2.2 and flTC-3 
as described [24] except that the nuclear proteins were finally dialyzed 
against two changes of 500 volumes of buffer (20 mM HEPES-KOH 
pH 7.9, 25% (v/v) glycerol, 50 mM KC1, 1.5 mM MgCI2, 0.5 mM PMSF, 
0.5 mM e-aminocapronic acid, and 2.5 pg/ml trasylol) at 4°C. In vitro 
DNase I footprinting assays as well as methylation i terference assays 
were performed according to [8]. Electrophoretic mobility shift assays 
(EMSAs) were carried out as described in[16,25]. Single-stranded de-
oxyoligonucleotides w re provided by Dr. E Oppermann, IBI EMAU 
Greifswald, Germany. Anti-IPF-l-antibodies (a generous gift from 
H. Edlund, Ume~t, Sweden) were used in EMSAs as a 1:10 diluted 
solution of the original antiserum [26]. 
3. Results 
3.1. The AT-rich region (-2121-196) of the rat insulin-H 
promoter contains an additional TAA T-motif 
Studying the role of the AT-rich region between ucleotides 
-212 and -196 of the rat insulin-II promoter, we observed a
sequence difference at position -211 compared to the previ- 
ously reported sequence [27], i.e. an adenosine instead of a 
cytidine (compare Accession No. X82162 with J00748). Due to 
the formation of a putative additional TAAT-motif at the lower 
DNA strand adjacent to the previously studied CT-2-box [16] 
here named TAAT2, we performed a more detailed sequence 
analysis. To verify that this base exchange represents he 'wild 
type' sequence, we analyzed genomic DNA from several differ- 
ent rat strains: Wistar, Sprague Dawley, BB-rats, and from 
DA-rats (both males and females in each case). The DNA 
region of interest was amplified by the PCR technique using 
separate reactions with either Taq polymerase from Th. 
aquaticus (Amersham) or Ultma-polymerase from Th. maritima 
(Perkin Elmer). To verify the DNA sequences we analyzed both 
DNA strands by using two different sequencing techniques: 
Sanger's technique [28] using the T7-DNA-polymerase s - 
quencing kit (Pharmacia) and cycle sequencing using the 'Dye 
Termination Technique' (Applied Biosystems). The resulting 
sequence is illustrated in Fig. IB as p211A and in Fig. 2. The 
findings obtained emonstrate that the sequence presented here 
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Fig. 1. (A) Transient expression of p211C and p211A in the insulin- 
producing cell line HIT M2.2.2. CAT values represent averages of at 
least hree individual experiments and are expressed aspercentages of 
p211C (= 100%). (B) Sequences represent the region between ucleo- 
tides -218 and -189 of the promoter fragments used in p211C and 
p211A. The base difference at position -211 is shown and the TAAT- 
motifs are delineated. 
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Fig. 2. Results ummarized from in vitro footprinting assays performed 
between ucleotides -278 and -163. The regions protected from 
DNase I digestion isbracketed, purines involved in methylation i ter- 
ference between nucleotides -218 and - 186 are shown as • when fully 
involved, or as © when partially involved. Position and sequences of the 
E-box-like motif and the TAAT-motifs within this region are shown. 
does represent the wild type situation for the rat insulin-II gene. 
One consequence of this observation is the formation of an 
additional TAAT-motif, i.e. TAAT3 (p211A, Fig. IB) at the 
lower strand directly upstream of the previously described 
TAAT-motif TAAT2. To prove the impact of TAAT3 on tran- 
scriptional control we performed both transient expression 
analysis as well as in vitro analysis of DNA-protein interac- 
tions. 
3.2. The newly identified TAAT-motif is involved in 
transcriptional control in vivo 
To study the functional relevance of the newly identified 
TAAT-motif TAAT3 on the regulation of gene expression, we 
performed transient expression studies in the insulin-producing 
cell line HIT M2.2.2. In these experiments we used expression 
constructs based on pBRINSII-218CAT [16] containing (i) the 
sequence containing a cytidine at -211 within its promoter 
fragment (Fig. 1B, p211C) and (ii) the 'wild-type' sequence 
containing an adenosine at this position (Fig. 1B, p211A). The 
results presented in Fig. 1A demonstrate hat the single-base 
difference caused a 2.3-fold increase in CAT expression i  HIT 
M2.2.2 cells and, therefore, show that the newly described 
TAAT-motif is involved in transcriptional control in vivo. 
3.3. The newly identified TAAT-mot!f is involved in DNA- 
protein interactions in vitro 
Performing in vitro footprinting experiments by methylation 
interference and DNase I treatment showed that both TAAT- 
motifs between -2121-207 bp and -201l-196 bp were pro- 
tected by DNA/protein interaction (Fig. 2). To further study 
the involvement of the identified TAAT-motifs of the rat insu- 
lin-II promoter in in vitro DNA-protein interactions, we used 
the following double-stranded oligonucleotides in electro- 
phoretic mobility shift assays: R2AT211A and R2AT211C 
(representing the DNA sequences between ucleotides -218 
and - 189 according to GenBank Acc. no. X82162 and J00748, 
respectively), R2TAAT2 (i.e. R2AT211A but with mutated 
TAAT3-motif), R2TAAT3 (i.e. R2AT211A but with mutated 
TAAT2-motif), and oligonucleotides containing the TAAT1- 
motifs of the rat insulin-I and -I1 promoters (R2TAAT1 and 
R1TAAT1, respectively), and the entire FLAT-element of the 
rat insulin-I promoter (R1FLAT). The sequences of these ol- 
igonucleotides are shown in Fig. 3. 
Using nuclear extracts prepared from the insulin-producing 
cell line HIT M2.2.2 in electrophoretic mobility shift assays, 
the oligonucleotide containing the AT-rich region of the rat 
212 I.B. Leibiger et aL /FEBS Letters 362 (1995) 210-214 
R?JL']~ l~k  AGCCCCTATTAAGACTCTAATTACCCTAAG 
TCGGGGATAATTCTGAGATTAATGGGATTC -218/ -  189 
R2AT211C AGCCCCTcTTAAGACTCTAATTACCCTAAG -218/ -189  
TCGGGGAgAATTCTGAGATTAATGGGATTC 
R2TAAT3 AGCCCCTATTAAGACgacgAcTACCCTAAG -218/ -189  
TCGGGGATAATTCTGct g cTgATGGGATTC 
RITAAT2 k£CCCCTgcTgAGACTCTAATTACCCTAAG - 218  / - 189  
TCGGGGAcgAcTCTGAGATTAATGGGATTC 
P.,2ThAT 1 TGCTGATCCACCCTTAATGGGACAAACAGG - 94 / - 65 
ACGACTAGGTGGGAATTAC CCTGTTTGTCG 
R IFL&T CCTTGTTAATAATCTAATTACCCTAGGTCT - 227/ -  198 
GGAACAATTATTAGATTAATGGGATCCAGA 
R ITAAT I  CCTCCTAGAC,~,CCTTAATGGGCCA,~ACGGG - 94 / - 65 
GGAGGATCTCGGGAATTACCCGGTTTGCCG 
Fig. 3. Position and sequence of oligonucleotide probes used for the 
analysis of protein binding in EMSAs and competition studies. O1- 
igonucleotides contain TAAT-motifs of the rat insulin-I promoter 
(RITAAT1, R1FLAT) and normal (R2TAATI, R2AT211A) and mu- 
tated (R2AT211C, R2TAAT2, R2TAAT3) regions of the rat insulin-II 
promoter. Positions of mutations within mutant oligonucleotides are 
shown as lower-case l tters. 
insulin-II promoter between nucleotides -216/-187, i.e. 
R2AT211A, led to the formation of three retarded complexes 
A, B, and C (Fig. 4A, lane 1). Surprisingly, the oligonucleotide 
containing the originally described sequence composition, i.e. 
R2AT211C, generated the same retardation pattern as seen 
from R2AT211A (Fig. 4A, lane 6). However, while changing 
the incubation conditions, especially the concentration f KC1, 
we observed a marked ifference in the retardation patterns of 
both probes: whereas increasing amounts of KCI from 16 mM 
to 200 mM led to a stronger formation of complex B for the 
wild-type variant R2AT211A (Fig. 4A, lanes 1-5) the same 
conditions caused at best a weak increase in the formation of 
complex B for R2AT211C (Fig. 4A, lanes 6 10). To study the 
protein-binding properties of the newly identified TAAT-motif 
on its own, we synthesized an oligonucleotide where the adja- 
cent upper-strand TAAT-motif was mutated, i.e. R2TAAT3 
(Fig. 3). In EMSAs R2TAAT3 formed only a single retarded 
complex (Fig. 4B, lane 4), very similar to complex B of 
R2AT211A (Fig. 4B, lane 1). The formation of this complex 
was abolished when using oligonucleotides containing the 
TAAT2-motif (R2TAAT2) or the TAATl-motif (R2TAAT1) 
as competitors (Fig. 4B, lanes 6 and 7, respectively). Further- 
more, R2TAAT3 as a competitor was able to reduce the forma- 
tion of all complexes A, B, and C (Fig. 4B, lane 3). 
3.4. The AT-rich region between -212 and -196 bp of the rat 
insulin-H promoter contains two binding sites for IPF-1 
IPF-I was shown to be the favored trans-acting factor bind- 
ing to the proximal TAAT-motif P1 of the rat insulin-I pro- 
moter but not to the distal E2 element (i.e. the FLAT-element 
[10]), where IEF2 binds when using nuclear extracts of the 
insulin-producing cell line flTC-1 [9]. 
To study whether the AT-rich region at -212/-  196 bp of the 
Prd~ 
KCI 
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Probe: r -R2AT211A- , r --R2TAAT 3 
Competitor:. /U  
A 
B 
C 
B 1 2 3 4 5 6 7 
Fig. 4. Binding of HIT M 2.2.2 nuclear proteins to oligonucleotides 
R2AT211A, R2AT211C, and R2TAAT3. (A) Labeled oligonucleotides 
R2AT211A (lanes 1-5) and R2AT211C (lanes 6-10) were incubated 
with nuclear proteins in the presence ofincreasing amounts of KCI: 16 
mM (lanes 1 and 6), 50 mM (lanes 2 and 7), 100 mM (lanes 3 and 8), 
150 mM (lanes 4 and 9), and 200 mM (lanes 5 and 10), respectively. 
(B) Labeled oligonucleotides R2AT211A (lanes 1-3) and R2TAAT3 
(lanes 4-7) were incubated in the presence of 150 mM KC1. The indi- 
cated unlabeled competitor oligonucleotides were used in approxi- 
mately 100- fold molar excess. 
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rat insulin-II promoter is a target of IPF-1, we performed 
electrophoretic mobility shift assays using nuclear extracts pre- 
Probe: 
Anti-IPFl-antiserum: + + + + 
A 
PPobe'. 
Anti. lPFl.antiserum: 
2 3 4 5 6 7 8 
0:--,,- 
+ - + + 
qlIRO " f lb* .~g ID~ 
B 1 2 3 4 5 6 
Fig. 5. Binding of flTC-3 nuclear proteins to oligonucleotide probes 
corresponding to TAAT-motifs of rat insulin-I and -II promoters ( ee 
Fig. 3). Protein binding to the indicated labeled probes was performed 
with (+) or without (-) a pre-incubation f the nuclear extracts with 
anti-IPF-1 antiserum for 10 min at room temperature. The arrowheads 
indicate the position of IPF-l-containing complexes. (A) Binding of 
treated and untreated nuclear proteins to oligonucleotides containing 
the proximal or distal TAAT-motifs of rat insulin-I promoter 
(R1TAAT1 and R1FLAT, respectively), and rat insulin-II promoter 
(R2TAAT1 and R2AT211A, respectively). (B) Binding of treated and 
untreated nuclear proteins to oligos containing the intact distal AT-rich 
region with the combination of both TAAT2 and TAAT3 motifs 
(R2AT211A), or to mutant oligos containing either the TAAT2-motif 
(R2TAAT2) or TAAT3-motif (R2TAAT3) alone. 
pared from flTC-3, a cell line very similar to flTC-I [29]. As a 
positive control we used an oligonucleotide containing the 
proximal TAAT-motif ( -  80/- 74 bp) of the rat insulin-I pro- 
moter (R1TAAT1), and as a negative control the FLAT-ele- 
ment (R1FLAT), i.e. the rat insulin-I promoter AT-rich region 
between -222/-208 bp. The EMSAs revealed similar retarda- 
tion pattern for oligonucleotides containing the rat insulin-I 
IPF-1 binding site (R1TAAT1), the proximal TAAT-motif 
(R2TAAT1) and the AT-rich region between -212 and -196 
bp (R2AT211A) of the rat insulin-II promoter (Fig. 5A, lanes 
l, 5, 7, respectively). Addition of antibodies raised against the 
DNA-recognition part of IPF-1 lead to a loss in DNA-binding 
to both rat insulin-II AT-rich regions (Fig. 5A, lanes 6, 8). On 
the contrary, in the rat insulin-I promoter only the proximal 
TAAT-motif showed a loss in binding of IPF-1 when using the 
antibody (Fig. 5A, lane 2). When the IPF-l binding properties 
of the two TAAT-motifs of the rat insulin-II AT-rich region 
were studied separately, both TAAT-motifs were able to bind 
protein complexes, which disappeared upon inclusion of anti- 
bodies raised against IPF-1 (Fig. 5B, lanes 4, 5). As expected, 
the FLAT-element of the rat insulin-I promoter formed re- 
tarded complexes different from those seen with the equivalent 
AT-rich region of the rat insulin-II promoter (Fig. 5A, lane 3), 
and these complexes were insensitive to treatment with anti- 
IPF-I antibodies (Fig. 5A, lane 4). 
4. Discussion 
Previous studies on insulin gene regulation by different 
groups have confirmed the involvement of TAAT-motifs in 
transcriptional control (8-17,30-32). TAAT-motifs were 
shown to be the binding core for homeodomain-containing 
transcription factors [33]. Several trans-acting factors were re- 
ported to bind to insulin TAAT-motifs: IUF-1 [11,12,14], isl-1 
[31], IPF-1 [26] and IEF-2 [9], lmx-1 and cdx-3 [32], STF-1/IPF- 
1 [15], STF-1/IPF-1/IDX-1 [17]. In a previous report we demon- 
strated that TAAT-motifs of the rat insulin-II promoter be- 
tween nucleotides -83/ -76 and -204/-197 are mutationally 
sensitive and contribute totranscriptional control [16]. Further- 
more, we found a difference in the nucleotide composition 
within the AT-rich region at - 212/- 196 at position - 211 com- 
pared to the originally described sequence [27], i.e. an adenosine 
instead of a cytidine. One consequence of that sequence differ- 
ence is the formation of an additional TAAT-motif on the 
complementary strand directly upstream of the well studied 
TAAT2-motif [16]. Here we present evidence that this sequence 
represents he 'wild type' situation for the rat insulin-II pro- 
moter for at least four different rat strains: Wistar, Sprague 
Dawley, DA, and BB-rats. As demonstrated byin vitro DNA- 
protein interaction analysis this region is protected from DNase 
I digestion and is also involved in methylation i terference (Fig. 
2). Although the observed sequence difference at position - 211 
did not lead to a changed retardation pattern in EMSA at 16 
mM KCI, the formation of these complexes i clearly different 
under increasing concentrations of KCI (Fig. 4A). This might 
be the reason for the more than 2.3-fold difference in CAT 
expression using constructs with both sequence variants (Fig. 
1A). The differences in retardation patterns and binding affin- 
ities of the same oligonucleotide probes in figures 4 and 5 is 
caused by the use of nuclear extracts of different species, ham- 
ster insulinoma (Fig. 4) and mouse insulinoma (Fig. 5). Con- 
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cerning the involvement of the TAAT2- motif in transcriptional 
control, our previous observation [16] was confirmed by Pe- 
shavaria et al. [17] showing furthermore that this motif is a 
binding site for a homeodomain-containing protein very similar 
to STF-1/IPF-1/IDX-1 and related to the endoderm-specific 
Xenopus laevis homeodomain protein XlHbox8. Since the insu- 
lin promoter factor 1, i.e. IPF-1, was demonstrated to be iden- 
tical to a part of X1Hbox8 [26] and to be the favored binding 
factor for the proximal rat insulin-I TAAT-motif, i.e. to the 
Pl-region [9], we investigated the binding of IPF-1 to the AT- 
rich region of the rat insulin-II promoter located between u- 
cleotides - 212 and - 196. Using nuclear extracts prepared from 
flTC-3 as well as antibodies raised against IPF-I in electro- 
phoretic mobility shift assays we demonstrate hat not only the 
previously reported TAAT-motifs TAAT1 and TAAT2, but 
also the newly identified motif TAAT3, is a binding target of 
IPF-1. Additionally our studies confirm the findings by Ohls- 
son et al. [9] showing that the two TAAT-containing regions 
within the rat insulin-I promoter, i.e. P1 and E2 (FLAT), repre- 
sent binding sites for different rans-acting factors. Our obser- 
vations are also in agreement with those of German et al. [10] 
that different trans-acting factors are involved in complex- 
formation of the AT-rich regions of the rat insulin-I and -II 
promoters. The fact, that TAAT2/TAAT3 is a binding site for 
IPF-1, and the absence of a correct Far-element 
(GCCATCTG) in the correct juxtaposition to the AT-rich re- 
gion of the rat insulin-II promoter, may contribute to the 
marked difference observed in the transcriptional control of 
both rat insulin genes, i.e. the promoter egion of the rat insu- 
lin-II gene similar to the rat insulin-I FF-minienhancer does not 
exhibit enhancer properties ([10], own observations, data not 
shown). On the other hand we found that IPF-I binding is not 
restricted to the promoters of different insulin genes. IPF-1 is 
also a trans-acting factor binding to TAAT-motifs of further 
fl-cell-active promoters, such as the rat glucokinase upstream 
promoter, the rat amylin gene promoter, and the human glu- 
cose transporter-2 gene promoter (I.B. Leibiger, unpublished 
data). Theses findings upport our previous assumption, based 
on EMSA studies, that TAAT-motifs of the genes mentioned 
above may use similar, if not identical, trans-acting factors [25]. 
In this way, IPF-1, or related factors such as IUF-1 [11], STF-1 
[34], or IDX-1 [35], may represent one of the central factors 
responsible for fl-cell-active and islet-specific transcriptional 
control, and, furthermore, may be involved in the coordinated 
regulation of pancreatic fl-cell expressed genes. 
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